NA-miR-128-3p can be combined with orexin B to significantly affect HCC progression by interfering with the VEGF and PI3K-AKT pathways [121,122], which is a new co-administration strategy and provides a new idea for HCC treatment. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.